Literature DB >> 2921499

Low-dose ursodeoxycholic acid prolongs cholesterol nucleation time in gallbladder bile of patients with cholesterol gallstones.

D Jüngst1, G Brenner, E Pratschke, G Paumgartner.   

Abstract

The high rate of stone recurrence represents a drawback of non-surgical therapy of cholesterol gallstone disease. Although most studies report that long-term bile acid treatment does not have protective effects, preliminary results suggest that low-dose ursodeoxycholic acid decreases the rate of gallstone recurrence in a subgroup of younger patients. To clarify the underlying mechanism we investigated whether low-dose ursodeoxycholic acid treatment influences biliary cholesterol saturation and/or nucleation time of cholesterol. Ten patients with cholesterol gallstones and functioning gallbladder received 250 mg ursodeoxycholic acid/day at bedtime 6-10 days prior to cholecystectomy. Eleven patients with cholesterol gallstones without treatment served as controls. Cholesterol crystals were present in the gallbladder bile of 7 out of the 10 patients receiving ursodeoxycholic acid and in all control biles. Ursodeoxycholic acid treatment significantly (P less than 0.02) decreased the cholesterol saturation index (mean +/- S.E.: 0.94 +/- 0.05 vs. 1.43 +/- 0.18) and led to an approximately 5-fold prolongation (P less than 0.005) of the cholesterol nucleation time (mean +/- S.E.: 12.0 +/- 2.4 vs. 2.3 +/- 0.7 days). We conclude that low-dose ursodeoxycholic acid might be effective in the prevention of post-dissolution gallstone recurrence by both decreasing cholesterol saturation and prolonging cholesterol nucleation time.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2921499     DOI: 10.1016/0168-8278(89)90154-2

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  6 in total

1.  Decreased protein concentration and improved metastability of bile induced by ursodeoxycholate.

Authors:  K Chijiwa; I Hirota; H Noshiro
Journal:  Gastroenterol Jpn       Date:  1992-02

2.  Gall stone recurrence and its prevention: the British/Belgian Gall Stone Study Group's post-dissolution trial.

Authors:  K A Hood; D Gleeson; D C Ruppin; R H Dowling
Journal:  Gut       Date:  1993-09       Impact factor: 23.059

3.  Effects of ileal resection on biliary lipids and bile acid composition in patients with Crohn's disease.

Authors:  A Lapidus; K Einarsson
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

4.  Nucleation time of gall bladder bile in gall stone patients: influence of bile acid treatment.

Authors:  S Sahlin; J Ahlberg; B Angelin; E Reihnér; K Einarsson
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

Review 5.  Roles of infection, inflammation, and the immune system in cholesterol gallstone formation.

Authors:  Kirk J Maurer; Martin C Carey; James G Fox
Journal:  Gastroenterology       Date:  2008-12-25       Impact factor: 22.682

6.  Telocytes: new insight into the pathogenesis of gallstone disease.

Authors:  Andrzej Matyja; Krzysztof Gil; Artur Pasternak; Krystyna Sztefko; Mariusz Gajda; Krzysztof A Tomaszewski; Maciej Matyja; Jerzy A Walocha; Jan Kulig; Piotr Thor
Journal:  J Cell Mol Med       Date:  2013-04-04       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.